###begin article-title 0
###xml 21 41 21 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 21 60 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 138 142 <span type="species:ncbi:10090">mice</span>
Use of a recombinant Salmonella enterica serovar Typhimurium strain expressing C-Raf for protection against C-Raf induced lung adenoma in mice
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 433 453 433 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 473 478 473 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 433 472 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 517 522 <span type="species:ncbi:10090">mouse</span>
Serine-threonine kinases of the Raf family (A-Raf, B-Raf, C-Raf) are central players in cellular signal transduction, and thus often causally involved in the development of cancer when mutated or over-expressed. Therefore these proteins are potential targets for immunotherapy and a possible basis for vaccine development against tumors. In this study we analyzed the functionality of a new live C-Raf vaccine based on an attenuated Salmonella enterica serovar Typhimurium aroA strain in two Raf dependent lung tumor mouse models.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 71 88 71 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli </italic>
###xml 152 177 148 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA Salmonella enterica </italic>
###xml 71 87 <span type="species:ncbi:562">Escherichia coli</span>
###xml 157 196 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 371 375 <span type="species:ncbi:10090">mice</span>
The antigen C-Raf has been fused to the C-terminal secretion signal of Escherichia coli alpha-hemolysin and expressed in secreted form by an attenuated aroA Salmonella enterica serovar Typhimurium strain via the alpha-hemolysin secretion pathway. The effect of the immunization with this recombinant C-Raf strain on wild-type C57BL/6 or lung tumor bearing transgenic BxB mice was analyzed using western blot and FACS analysis as well as specific tumor growth assays.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 75 95 75 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 137 145 137 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 75 114 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 137 144 <span type="species:ncbi:562">E. coli</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 374 379 <span type="species:ncbi:10090">mouse</span>
C-Raf antigen was successfully expressed in secreted form by an attenuated Salmonella enterica serovar Typhimurium aroA strain using the E. coli hemolysin secretion system. Immunization of wild-type C57BL/6 or tumor bearing mice provoked specific C-Raf antibody and T-cell responses. Most importantly, the vaccine strain significantly reduced tumor growth in two transgenic mouse models of Raf oncogene-induced lung adenomas.
###end p 7
###begin title 8
Conclusions
###end title 8
###begin p 9
###xml 69 89 69 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 69 108 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 213 218 <span type="species:ncbi:9606">human</span>
The combination of the C-Raf antigen, hemolysin secretion system and Salmonella enterica serovar Typhimurium could form the basis for a new generation of live bacterial vaccines for the treatment of Raf dependent human malignancies.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 147 148 147 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 149 150 149 150 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 498 499 498 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
The Raf proteins (A-Raf, B-Raf, C-Raf) are located upstream of MEK and downstream of Ras and represent an essential part of the mitogenic cascade [1-3]. Interestingly, Raf kinases are not only central players in cellular signal transduction, but are often causally involved in the development of cancer. Recently, B-Raf was found to be mutated in a broad range of malignancies including melanoma (more than 65%), and colon cancer [4]. In addition, overexpression of C-Raf was found in many tumors [5,6]. Therefore, these proteins are potential targets for immunotherapy as well as immunoprevention of tumors.
###end p 11
###begin p 12
###xml 82 102 82 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 122 127 122 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 294 295 294 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 357 365 357 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 430 441 426 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella </italic>
###xml 442 443 438 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 684 685 680 681 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s</sub>
###xml 947 949 943 945 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 1171 1191 1167 1187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 1211 1216 1207 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 82 121 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 357 364 <span type="species:ncbi:562">E. coli</span>
###xml 1171 1210 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 1331 1335 <span type="species:ncbi:10090">mice</span>
Here we describe the development of a C-Raf vaccine on the basis of an attenuated Salmonella enterica serovar Typhimurium aroA strain. Such recombinant live vaccines have been shown to efficiently elicit both, humoral and cellular immune responses against a variety of heterologous antigens [7,8]. In order to achieve stable expression of C-Raf we used the E. coli alpha-hemolysin (HlyA) secretion system which is fully active in Salmonella [9]. This transport machinery is the prototype of type I secretion systems and consists of three different components, namely HlyB, HlyD and TolC. The HlyA carries at its C-terminus a secretion signal of about 50-60 amino acids in length (HlyAs), which is recognized by the HlyB/HlyD/TolC-translocator, leading to direct secretion of the entire protein into the extracellular medium without the formation of periplasmic intermediates. In addition, fused to the C-terminus of heterologous proteins, the HlyAs leads to efficient secretion of such proteins by the recombinant bacteria. In our case, the whole C-Raf antigen fused to the C-terminal secretion signal of hemolysin was efficiently expressed and secreted by an attenuated Salmonella enterica serovar Typhimurium aroA strain. The effects of this recombinant vaccine were assessed in wild-type C57BL/6 or tumor bearing transgenic BxB mice.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
###xml 44 48 <span type="species:ncbi:10090">mice</span>
Bacterial strains, plasmids, cell lines and mice
###end title 14
###begin p 15
###xml 92 93 92 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 48 52 <span type="species:ncbi:10090">mice</span>
The bacterial strains, plasmids, cell lines and mice used in this study are listed in Table 1.
###end p 15
###begin title 16
###xml 26 46 26 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 26 65 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
Plasmid transformation in Salmonella enterica serovar Typhimurium SL7207
###end title 16
###begin p 17
###xml 72 92 72 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 238 240 238 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 241 243 241 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 287 307 287 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 355 375 355 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 72 111 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 229 236 <span type="species:ncbi:562">E. coli</span>
###xml 287 326 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 355 394 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
The plasmids pMOhly1 and pMOhly-Raf were first transformed in competent Salmonella enterica serovar Typhimurium LB5000 (Tab. 1), a restriction-negative and modification-proficient strain by a standard transformation protocol for E. coli [10,11]. Subsequently, the plasmids purified from Salmonella enterica serovar Typhimurium LB5000 were introduced into Salmonella enterica serovar Typhimurium SL7207 by electroporation using a Bio-Rad Gene Pulser (Hercules, CA, USA) at 2.5 kV, 25 microfarads (muF), and 200 Ohm in a 0.1 cm electroporation cuvette.
###end p 17
###begin title 18
Construction of the plasmid pMOhly-Raf
###end title 18
###begin p 19
###xml 37 43 37 43 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ATGCAT</underline>
###xml 94 100 94 100 <underline xmlns:xlink="http://www.w3.org/1999/xlink">ATGCAT</underline>
###xml 192 197 192 197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">craf </italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 483 488 465 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NsiI </italic>
###xml 538 543 520 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">craf </italic>
###xml 577 582 559 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NsiI </italic>
###xml 617 619 599 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 673 681 655 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 732 747 710 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. typhimurium </italic>
###xml 760 761 738 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 673 680 <span type="species:ncbi:562">E. coli</span>
###xml 732 746 <span type="species:ncbi:90371">S. typhimurium</span>
Sense primer 5' Raf: 5'-ATGGAGCACATACATGCATCTTGGAAG-3' and antisense primer 3'Raf: 5'-CAACTAGAATGCATGCAGCCTCGGGGA-3' were used to amplify by PCR a 1950 bp DNA fragment representing the entire craf gene from plasmid pUC13-c-raf-1 [12]. PCRs were performed in a Thermal Cycler 60 (Biometra, Gottingen, Germany) for 30 cycles of 94degreesC for 1 min, 55degreesC for 1 min, and 72degreesC for 90 s. After purification with the GeneClean Kit (Bio101, La Jolla, Ca) and digestion with the NsiI restriction enzyme, the DNA fragment carrying the craf gene was inserted into the single NsiI site of the export vector pMOhly1 [13]. The resulting plasmid pMOhly-Raf was isolated from E. coli DH5alpha (Invitrogen), analyzed and transformed in S. typhimurium SL7207 (Tab. 1) by electroporation.
###end p 19
###begin title 20
Western blot analysis
###end title 20
###begin p 21
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 219 223 212 216 <sub xmlns:xlink="http://www.w3.org/1999/xlink">600 </sub>
###xml 514 516 501 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 0 39 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 564 570 <span type="species:ncbi:9986">rabbit</span>
###xml 645 651 <span type="species:ncbi:9793">donkey</span>
###xml 657 663 <span type="species:ncbi:9986">rabbit</span>
###xml 690 701 <span type="species:ncbi:3704">horseradish</span>
Salmonella enterica serovar Typhimurium strains harbouring the recombinant plasmids pMOhly1 or pMOhly-Raf were cultivated at 37degreesC in BHI medium with 100 mug/ml ampicillin. Cells at the exponential growth phase (OD600 of 1) were centrifuged at 5000 x g at 4degreesC for 5 min. The supernatant proteins were precipitated with 10% (V/V) trichloroacetic acid (TCA) for 1 h on ice, collected by centrifugation and resuspended in SDS sample buffer. The supernatant proteins were separated on 10% gels by SDS-PAGE [14]. For immunodetection of Raf-HlyA proteins the rabbit polyclonal anti-Raf antibody SP-63 (diluted 1:1,000, Rapp Laboratory) and donkey anti-rabbit immunoglobulins linked to horseradish peroxidase (Amersham Pharmacia Biotech) diluted 1:1,000 as secondary antibodies were used. Blots were developed by enhanced chemiluminescence (ECL reagents; Amersham Biosciences, UK) and exposed on X-ray film (Kodak, XO-MAT-AR) for 1 min.
###end p 21
###begin title 22
###xml 26 46 26 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 26 65 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
Immunization of mice with Salmonella enterica serovar Typhimurium SL7207 strains
###end title 22
###begin title 23
Oral/intravenous prime boost protocol (p.o./i.v.)
###end title 23
###begin p 24
###xml 293 295 293 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink">9 </sup>
###xml 482 484 481 483 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 559 561 557 559 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 238 242 <span type="species:ncbi:10090">mice</span>
###xml 415 419 <span type="species:ncbi:10090">mice</span>
###xml 516 520 <span type="species:ncbi:10090">mice</span>
In order to achieve a broad immune response encompassing both, the mucosal and systemic immunity against C-Raf, we combined oral immunization (p.o.) with an intravenous (i.v.) boost. In these experiments, seven weeks old C57BL/6 or BxB23 mice were immunized, first p.o. three times with 5 x 109 bacteria/100 mul phosphate-bufferd saline (PBS) at 5-day intervals. At day 45 after the start of the vaccination, these mice were boosted intravenously (i.v.) with a single-dose of 5 x 105 bacteria/100 mul PBS. The BxB23 mice received a second i.v. boost of 5 x 105 bacteria at day 90 after the start of the vaccination. Induction of Raf-specific immune responses were analyzed at day 50 for C57BL/6 or at day 95 for BxB23 respectively.
###end p 24
###begin title 25
Intranasal Immunization (i.n.)
###end title 25
###begin p 26
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">7</sup>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
Seven weeks old BxB23 mice were immunized i.n. four times with 1 x 107bacteria/30 mul phosphate-buffered saline (PBS) at 14-day intervals. The vaccine was applied using a micropipette onto the nares of mice under anesthesia.
###end p 26
###begin p 27
Induction of Raf-specific immune responses were analyzed at day 70.
###end p 27
###begin title 28
###xml 28 32 <span type="species:ncbi:10090">mice</span>
###xml 38 77 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
I. n. Immunization of BXB11 mice with Salmonella enterica serovar Typhimurium SL7207/pMOhly-Raf
###end title 28
###begin p 29
###xml 70 71 70 71 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8</sup>
###xml 22 26 <span type="species:ncbi:10090">mice</span>
###xml 181 185 <span type="species:ncbi:10090">mice</span>
Four months old BXB11 mice were immunized i.n. three times with 1 x 108salmonellae in 10 mul PBS at 14-day intervals. The vaccine was applied using a micropipette into the nares of mice without anesthesia.
###end p 29
###begin title 30
Construction of a C-Raf overexpressing EL-4 cell line
###end title 30
###begin p 31
###xml 196 198 196 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 214 215 214 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 161 167 <span type="species:ncbi:10090">murine</span>
In order to create tools for analysis of C-Raf specific T cells we first constructed a C-Raf overexpressing EL-4 cell line (ELRaf). The EL4 tumor cell line is a murine thymoma cell line of the H-2b haplotype (Tab. 1). 10 mug purified DNA of plasmid pDNA3craf was introduced into EL4 cells by electroporation with the Bio-Rad Gene Pulser (Hercules, CA) at 0.25 kV, 960 muFD, in a 0.4-cm electroporation cuvette. The transformed cells were grown RPMI 1640 medium (Invitrogen) supplemented with 5% (vol/vol) FCS (PAN Systems) and 600 mug/ml G418 (Sigma). C-Raf is highly expressed in ELRaf cells (data not shown).
###end p 31
###begin title 32
###xml 41 43 41 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Flow cytometric detection of specific CD8+ T-cells
###end title 32
###begin title 33
Isolation of spleen cells
###end title 33
###begin p 34
###xml 328 332 <span type="species:ncbi:9913">calf</span>
Animals were sacrificed and a single cell suspension of splenocytes was prepared by passage of the spleen through a sieve into RP 10 medium [RPMI medium (Life Technologies) supplemented with glutamine (1%), 50 muM beta-mercaptoethanol (ROTH, Wuerzburg), penicillin (10 U/ml, GIBGO), streptomycin (100 U/ml, GIBGO) and 10% fetal calf serum (PANtrade mark, BIOTECH GmbH).
###end p 34
###begin p 35
###xml 98 99 98 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
The cell suspension was centrifuged and resuspended in 3 ml lysis buffer (5 mM Tris-HCl, 140 mM NH4Cl, pH 7.3) for the lysis of erythrocytes. After 2 minutes, 10 ml RP 10 medium was added to stop lysis. After centrifugation, cells were resuspended in 2 ml RP 10 medium and counted.
###end p 35
###begin title 36
Restimulation
###end title 36
###begin p 37
###xml 152 153 144 145 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 161 163 153 155 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 214 216 206 208 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
###xml 266 268 258 260 <sup xmlns:xlink="http://www.w3.org/1999/xlink">5 </sup>
In 6 ml FACS tubes and a total volume of 100 mul RP 10 medium in the presence of 30 U/ml recombinant IL-2 and 10 mug/ml Brefeldin A at 37degreesC, 5% CO2, 1 x 106 spleen cells were incubated for 5 hours with 5 x 105 C-Raf overexpressing EL-4 cells (EL-Raf) or 5 x 105 EL-4 cells or with the addition of 10 ng/ml of phorbol myristyl acetate (PMA; Sigma) and 500 ng/ml of ionomycin (Sigma) or with medium alone.
###end p 37
###begin title 38
Staining
###end title 38
###begin p 39
###xml 53 59 <span type="species:ncbi:9913">bovine</span>
###xml 599 602 <span type="species:ncbi:10116">rat</span>
###xml 740 743 <span type="species:ncbi:10116">Rat</span>
After restimulation, cells were washed with PBS-0.1% bovine serum albumin (BSA; P-B buffer) and incubated with 1 mul of anti-CD8-CyChrome (Pharmingen Nr. 01082A) in a volume of 100 mul PBS-0.1% BSA for 20 min on ice. Subsequently, cells were washed and fixed for 20 min at room temperature with PBS-2% paraformaldehyde (Sigma). After washing with PBS-0.1% (BSA), cells were permeabilized with PBS-0.1% BSA-0.5% saponin (Sigma, P-B-S) buffer. After incubation for 5 min at room temperature, cells were washed with P-B-S buffer and incubated in a volume of 100 mul at room temperature with polyclonal rat immunoglobulin G (IgG) antibodies (JacksonImmunoResearch) to block nonspecific binding and 1 mul anti-IFN-gamma-FITC (AN18.17.24; XMG1.2 Rat IgG1; Pharmingen) for 20 min. After incubation, cells were washed twice with P-B-S buffer and another time with P-B buffer. Cells were resuspended in 400 mul PBS-PFA 0,5% and kept at 4degreesC until analysis.
###end p 39
###begin title 40
Analysis
###end title 40
###begin p 41
###xml 295 297 291 293 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
Cells were analyzed by flow cytometry in a FACS Calibur flow cytometer (Becton Dickinson) using CellQuest 3.0 software (Becton Dickinson). Lymphocytes were chosen according to their size and granularity in a forward/side - scatter diagram. Numbers are expressed as percent IFN-gamma positive CD8+ cells.
###end p 41
###begin title 42
Statistical analysis
###end title 42
###begin p 43
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 160 162 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The statistical significance of differential findings between experimental groups was determined by Student's t test. Findings were regarded as significant, if P values were <0.05. Survival curves were compared using a log rank test.
###end p 43
###begin title 44
Results
###end title 44
###begin title 45
###xml 59 79 59 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 59 98 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
Creation of a C-Raf vaccine on the basis of the attenuated Salmonella enterica serovar Typhimurium strain SL7207
###end title 45
###begin p 46
###xml 35 55 35 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">craf </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 311 322 311 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">craf-hlyAs </italic>
###xml 352 357 352 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hlyB </italic>
###xml 361 366 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hlyD </italic>
###xml 405 406 405 406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 413 428 413 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. typhimurium </italic>
###xml 595 596 595 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 35 74 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 150 155 <span type="species:ncbi:9606">human</span>
###xml 413 427 <span type="species:ncbi:90371">S. typhimurium</span>
The construction of the attenuated Salmonella enterica serovar Typhimurium aroA strain SL7207 secreting the C-Raf antigen was achieved by cloning the human craf cDNA from pUC13-c-raf-1 [12] into the vector plasmid pMOhly1 [13] as described in materials and methods. The resulting plasmid pMOhly-Raf carried the craf-hlyAs fused gene and the functional hlyB and hlyD genes required for its secretion (Fig. 1). The S. typhimurium SL7207/pMOhly-Raf strain efficiently expressed and secreted the hybrid C-Raf protein, as shown by immunoblotting with polyclonal antibodies raised against C-Raf (Fig. 2). The amount of secreted C-Raf was 2-3 mug protein/ml supernatant under the experimental conditions.
###end p 46
###begin title 47
###xml 26 30 <span type="species:ncbi:10090">mice</span>
Raf-specific responses of mice after immunization with recombinant SL7207/pMOhly-Raf
###end title 47
###begin p 48
###xml 263 283 263 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 363 383 363 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 610 611 610 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 632 633 632 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 639 656 639 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">Additional file 1</xref>
###xml 148 152 <span type="species:ncbi:10090">mice</span>
###xml 187 191 <span type="species:ncbi:10090">mice</span>
###xml 263 302 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 363 402 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 532 536 <span type="species:ncbi:10090">mice</span>
###xml 738 742 <span type="species:ncbi:10090">mice</span>
###xml 846 850 <span type="species:ncbi:10090">mice</span>
The efficacy of the recombinant bacterial strain to induce a Raf-specific immune response was analyzed using wild-type C57BL/6 and transgenic BxB23 mice. Groups of five C57BL/6 and BxB23 mice at the age of 7 weeks were immunized p.o./i.v or i.n. with recombinant Salmonella enterica serovar Typhimurium SL7207 secreting C-Raf antigen (SL7207/pMOhly-Raf) and with Salmonella enterica serovar Typhimurium SL7207 as control in order to test the induction of Raf-specific immune responses. The data showed that 20% of the sera of BxB23 mice immunized with SL7207/pMOhly-Raf contained Raf-specific antibodies (Fig. 3; supplementary Fig. 1 [see Additional file 1]). In contrast, no Raf-specific IgG response was detectable in the sera of BxB23 mice immunized with SL7207 alone (data not shown). Similar data were obtained after immunization of C57BL/6 mice with SL7207/pMOhly-Raf and SL7207 (data not shown).
###end p 48
###begin p 49
###xml 329 331 325 327 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 485 486 481 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 580 582 576 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 58 62 <span type="species:ncbi:10090">mice</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 508 512 <span type="species:ncbi:10090">mice</span>
###xml 534 538 <span type="species:ncbi:10090">mice</span>
###xml 922 926 <span type="species:ncbi:10090">mice</span>
To assess the induction of Raf-specific T-cell responses, mice were sacrificed and Raf specific T-cell responses were assessed using intracellular IFN-gamma staining followed by FACS analysis. For this purpose, T-cells were restimulated with C-Raf overexpressing EL-4 cells. Using this technique, we could detect Raf specific CD8+ T-cell response in C57BL/6 animals immunized p.o./i.v. with SL7207/pMOhly-Raf only but not in mice immunized i.n. or with the control strain SL7207 (Fig. 4). In immunized BxB23 mice, but not naive BxB23 mice, a high background and variability of CD8+ IFN-gamma positive cells even with non-specific stimulation was observed in two independent experiments. Therefore it was not possible to assess specific T-cell responses in this setting. Interestingly, the level of T-cells which responded to polyclonal stimulation by PMA / ionomycin was also reduced about 4 fold in comparison to C57BL/6 mice (data not shown).
###end p 49
###begin title 50
###xml 0 20 0 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 0 39 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
Salmonella enterica serovar Typhimurium SL7207/pMOhly-Raf strain induced partial protection against lung cancer in transgenic mouse models of Raf oncogene-induced lung adenomas
###end title 50
###begin p 51
###xml 83 94 83 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella </italic>
###xml 217 237 217 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 682 683 682 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 140 144 <span type="species:ncbi:10090">mice</span>
###xml 217 256 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 317 321 <span type="species:ncbi:10090">mice</span>
###xml 473 477 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
###xml 671 675 <span type="species:ncbi:10090">mice</span>
To test the protective capacity of the immune responses induced by the recombinant Salmonella strains, groups of 6 to 10 heterozygous BxB23 mice at the age of 7 weeks were immunized p.o./i.v. or i.n. with recombinant Salmonella enterica serovar Typhimurium strain (SL7207/pMOhly-Raf) or with SL7207 as control. BxB23 mice normally show an induction of lung adenomas with short latency and at 100% incidence [15,16]. The development of lung adenomas in the vaccinated BxB23 mice was assessed for 13 months. Our analysis revealed a significantly delayed tumor growth (reduction of lung weight) in mice immunized i.n. or p.o./i.v. with SL7207/pMOhly-Raf compared to control mice (Fig. 5).
###end p 51
###begin p 52
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">craf </italic>
###xml 198 200 198 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 192 196 <span type="species:ncbi:10090">mice</span>
###xml 228 232 <span type="species:ncbi:10090">mice</span>
###xml 321 325 <span type="species:ncbi:10090">mice</span>
In order to confirm these data we repeated the protection experiments using BxB11, another craf transgenic strain, which develop lung adenomas after a shorter latency period compared to BxB23 mice [15]. In this case, 66% of the mice immunized with SL7207/pMOhly-Raf survived at least three months longer than the control mice (Fig. 6).
###end p 52
###begin p 53
###xml 151 156 <span type="species:ncbi:10090">mouse</span>
These results suggest that the immunization with the vaccine strain SL7207/pMOhly-Raf can achieve a partial protection against tumor growth in the BxB mouse model.
###end p 53
###begin title 54
Discussion
###end title 54
###begin p 55
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
The major problems for vaccine development against cancer are the heterogeneity of the tumor cells and the fact that all tumor antigens are self-antigens. Therefore specific T-cells might be anergic or tolerant [17,18].
###end p 55
###begin p 56
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
However, despite these problems, several cancer vaccines have already reached clinical trials [19]. The success of these vaccines seems to be dependent on the target antigen and on the tumor type.
###end p 56
###begin p 57
###xml 127 147 127 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 224 229 224 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 430 431 430 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 467 483 467 483 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA Salmonella </italic>
###xml 538 540 538 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 541 543 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 558 583 558 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA Salmonella enterica </italic>
###xml 695 697 695 697 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 127 166 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 410 416 <span type="species:ncbi:9606">humans</span>
###xml 563 602 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 689 693 <span type="species:ncbi:10090">mice</span>
Here we describe a new strategy for achieving an anti-tumor immune response with a C-Raf vaccine on the basis of an attenuated Salmonella enterica serovar Typhimurium aroA strain as a "live vaccine". In general, recombinant aroA salmonellae are efficient live bacterial vectors that stimulate strong mucosal immunity, humoral and cell-mediated responses with a great potential as live vaccine carriers in both humans and animals [7,20]. Advantages of live attenuated aroA Salmonella vaccines include their safety and easy administration [21,22]. In addition aroA Salmonella enterica serovar Typhimurium strains were already successfully used as carriers for DNA vaccines against cancer in mice [23].
###end p 57
###begin p 58
###xml 77 97 77 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 139 147 139 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 334 335 334 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 377 397 377 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 417 422 417 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 635 655 635 655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 721 723 721 723 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 77 116 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 139 146 <span type="species:ncbi:562">E. coli</span>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
###xml 377 416 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 588 592 <span type="species:ncbi:10090">mice</span>
###xml 615 619 <span type="species:ncbi:10090">mice</span>
###xml 635 674 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 929 934 <span type="species:ncbi:9606">human</span>
###xml 1214 1220 <span type="species:ncbi:9606">humans</span>
###xml 1494 1499 <span type="species:ncbi:9606">human</span>
In this study the C-Raf antigen was delivered in secreted form by attenuated Salmonella enterica serovar Typhimurium aroA strain using the E. coli hemolysin secretion system. This system allows an efficient antigen secretion and presentation, which are necessary for an optimal immune response against the given heterologous antigen [9]. In fact, immunization of mice with the Salmonella enterica serovar Typhimurium aroA strain SL7207 secreting C-Raf resulted in the induction of a humoral immune response, manifested by the presence of Raf-specific antibodies in some of the vaccinated mice. In addition, C57BL/6 mice immunized with Salmonella enterica serovar Typhimurium SL7207/pMOhly-Raf developed a Raf-specific CD8+ T-cell response. The C-Raf vaccine thus is able to break the peripheral tolerance of the immune system towards C-Raf and to induce a specific immune response. Although the transgenic model is closer to the human setting in comparison to challenge models with tumor cell lines, we can not formally exclude that lung specific expression of the transgene in our BxB model is not sufficient for the induction of peripheral tolerance. Furthermore, side effects due to autoimmunity might occur in humans who have a more generalized expression pattern. However, the lung tissue does not belong to immunoprivileged sites and we have never observed any signs of lung pathology in immunized animals which strongly suggests that the data could, in principle, be translated into the human setting.
###end p 58
###begin p 59
###xml 116 136 116 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 501 503 497 499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 985 987 981 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 988 990 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 75 79 <span type="species:ncbi:10090">mice</span>
###xml 116 155 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 581 585 <span type="species:ncbi:10090">mice</span>
###xml 606 610 <span type="species:ncbi:10090">mice</span>
###xml 837 842 <span type="species:ncbi:9606">human</span>
###xml 975 983 <span type="species:ncbi:9606">patients</span>
We demonstrated also a partial tumor protection both in BxB23 and in BxB11 mice after immunization with recombinant Salmonella enterica serovar Typhimurium SL7207/pMOhly-Raf. However, we were not able to assess Raf specific CTL responses in these mice due to the high variability and background and therefore we cannot conclude whether protection is really due to cytotoxic T-cells or might be the result of other effects, e.g. an increased intratumoral level of IFN-gamma produced by Raf specific CD4+ T-cells. Interestingly, the observed variation occurred only in treated BxB23 mice, not in naive BxB23 mice. Therefore, the observed effect might be due to a spontaneous induction of an immune response mediated by tumor infiltrating bacteria. It is interesting to note that spontaneous Raf specific immune responses also occur in the human context, which we have recently demonstrated B-Raf V599E specific CTL and B-Raf /B-Raf V599E specific humoral responses in melanoma patients [24,25].
###end p 59
###begin p 60
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 157 159 157 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Most importantly, the lack of B-Raf V599E mutations in metastases of melanoma patients with strong B-Raf V599E CD8 response [24] supports the notion that CD8+ T-cells are effective in eliminating antigen positive tumor cells. The combined data thus provide proof of concept for the development of Raf-based anti-cancer vaccines.
###end p 60
###begin p 61
###xml 49 57 49 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 143 163 143 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 268 288 268 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 318 329 318 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella </italic>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 440 449 440 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. typhi </italic>
###xml 49 56 <span type="species:ncbi:562">E. coli</span>
###xml 143 182 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 268 301 <span type="species:ncbi:90370">Salmonella enterica serovar Typhi</span>
###xml 359 364 <span type="species:ncbi:9606">human</span>
###xml 440 448 <span type="species:ncbi:90370">S. typhi</span>
This is the first example demonstrating that the E. coli hemolysin secretion system is a versatile tool for the delivery of cancer antigens in Salmonella enterica serovar Typhimurium. Moreover, we have recently shown that this secretion system is also fully active in Salmonella enterica serovar Typhi Ty21a, the only Salmonella vaccine strain registered for human use [26]. Therefore, the combination of the hemolysin secretion system and S. typhi Ty21a could form the basis for a new generation of live bacterial vaccines against cancer.
###end p 61
###begin title 62
Conclusions
###end title 62
###begin p 63
###xml 120 140 120 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 160 165 160 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">aroA </italic>
###xml 187 195 187 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli </italic>
###xml 333 344 333 344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella </italic>
###xml 120 159 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
###xml 187 194 <span type="species:ncbi:562">E. coli</span>
###xml 291 306 <span type="species:ncbi:10090">transgenic mice</span>
###xml 508 513 <span type="species:ncbi:10090">mouse</span>
Taken together we have demonstrated that the C-Raf antigen can be successfully expressed and secreted by the attenuated Salmonella enterica serovar Typhimurium aroA SL7207 strain via the E. coli hemolysin secretion system. In addition, the immunization of wild-type C57BL/6 or tumor bearing transgenic mice with this C-Raf secreting Salmonella strain provoked specific C-Raf antibody and T cell responses. Most importantly, the vaccine strain induced partial protection against lung cancer in two transgenic mouse models of Raf oncogene-induced lung adenomas.
###end p 63
###begin p 64
The approach may provide a new strategy for the rational design of cancer therapies.
###end p 64
###begin title 65
Competing interests
###end title 65
###begin p 66
The author(s) declare that they have no competing interests.
###end p 66
###begin title 67
Authors' contributions
###end title 67
###begin p 68
###xml 225 229 <span type="species:ncbi:10090">mice</span>
IG, JF and JT designed the study. IG drafted the manuscript. JF was also involved in writing the report. AS and JF did the FACS analyses. JT constructed the EL4Raf cell line. TP, AS, JF and IG carried out the immunization of mice and the Western blot analyses. WG and URR were involved in providing the conceptual framework for this study. All authors approved the final version of the manuscript.
###end p 68
###begin title 69
Pre-publication history
###end title 69
###begin p 70
The pre-publication history for this paper can be accessed here:
###end p 70
###begin p 71

###end p 71
###begin title 72
Supplementary Material
###end title 72
###begin title 73
Additional File 1
###end title 73
###begin p 74
###xml 21 22 21 22 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
Supplementary figure 1: C-Raf-specific IgG in sera of p.o/i.v. (A) or i.n (B) immunized BxB23 mice (serum dilution 1:1000) demonstrated by western blotting. Supplementary figure with WESTERN Blot analysis of positive C-Raf sera.
###end p 74
###begin p 75
Click here for file
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
We would like to thank G. Dietrich and J.C. Becker for helpful discussions and Z. Sokolovic and H. Drexler for critical reading of the manuscript. This work was supported by grants from the Bavarian Research Cooperations Abayfor (Forimmun T3), Theraimmune GmbH (Wuerzburg) and the Fond der Chemischen Industrie.
###end p 77
###begin article-title 78
Raf meets Ras: completing the framework of a signal transduction pathway
###end article-title 78
###begin article-title 79
The ins and outs of Raf kinases
###end article-title 79
###begin article-title 80
Isotype-specific functions of Raf kinases
###end article-title 80
###begin article-title 81
###xml 30 35 <span type="species:ncbi:9606">human</span>
Mutations of the BRAF gene in human cancer
###end article-title 81
###begin article-title 82
###xml 96 101 <span type="species:ncbi:9606">human</span>
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
###end article-title 82
###begin article-title 83
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
###end article-title 83
###begin article-title 84
Concepts in Vaccine Development, Recombinant bacteria as vaccine carriers of heterologous antigens,
###end article-title 84
###begin article-title 85
Recent advances with recombinant bacterial vaccine vectors
###end article-title 85
###begin article-title 86
###xml 4 11 <span type="species:ncbi:562">E. coli</span>
The E. coli alpha-hemolysin secretion system and its use in vaccine development
###end article-title 86
###begin article-title 87
###xml 65 81 <span type="species:ncbi:562">Escherichia coli</span>
A rapid and highly efficient method for preparation of competent Escherichia coli cells
###end article-title 87
###begin article-title 88
###xml 68 84 <span type="species:ncbi:562">Escherichia coli</span>
Prolonged incubation in calcium chloride improves the competence of Escherichia coli cells
###end article-title 88
###begin article-title 89
###xml 36 41 <span type="species:ncbi:9606">human</span>
The complete coding sequence of the human raf oncogene and the corresponding structure of the c-raf-1 gene
###end article-title 89
###begin article-title 90
###xml 54 70 <span type="species:ncbi:562">Escherichia coli</span>
Development of antigen-delivery systems, based on the Escherichia coli hemolysin secretion pathway
###end article-title 90
###begin article-title 91
Cleavage of structural proteins during the assembly of the head of bacteriophageT4
###end article-title 91
###begin article-title 92
###xml 50 65 <span type="species:ncbi:10090">transgenic mice</span>
Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein
###end article-title 92
###begin article-title 93
Bcl-2 determines susceptibility to induction of lung cancer by oncogenic Craf
###end article-title 93
###begin article-title 94
###xml 69 74 <span type="species:ncbi:9606">human</span>
Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells
###end article-title 94
###begin article-title 95
###xml 34 39 <span type="species:ncbi:9606">human</span>
Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors
###end article-title 95
###begin article-title 96
Clinical cancer vaccine trials
###end article-title 96
###begin article-title 97
###xml 63 96 <span type="species:ncbi:90370">Salmonella enterica serovar Typhi</span>
Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors
###end article-title 97
###begin article-title 98
Oral immunization using live attenuated Salmonella spp. as carriers of foreign antigens
###end article-title 98
###begin article-title 99
The use of live attenuated Salmonella for oral vaccination
###end article-title 99
###begin article-title 100
DNA vaccines suppress tumor growth and metastases by the induction of anti-angiogenesis
###end article-title 100
###begin article-title 101
###xml 40 45 40 45 <sup xmlns:xlink="http://www.w3.org/1999/xlink">V599E</sup>
Immunogenicity of constitutively active V599EBRaf
###end article-title 101
###begin article-title 102
###xml 46 54 <span type="species:ncbi:9606">patients</span>
B-Raf specific antibody responses in melanoma patients
###end article-title 102
###begin article-title 103
###xml 47 63 <span type="species:ncbi:562">Escherichia coli</span>
###xml 92 108 <span type="species:ncbi:90370">Salmonella typhi</span>
Use of the alpha-hemolysin secretion system of Escherichia coli for antigen delivery in the Salmonella typhi Ty21a vaccine strain
###end article-title 103
###begin article-title 104
###xml 93 109 93 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 93 109 <span type="species:ncbi:562">Escherichia coli</span>
Characterization of a sequence (hlyR) which enhances synthesis and secretion of hemolysin in Escherichia coli
###end article-title 104
###begin article-title 105
Apoptosis regulation by interaction of Bcl-2 protein and Raf-1 kinase
###end article-title 105
###begin title 106
Figures and Tables
###end title 106
###begin p 107
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hlyC</italic>
###xml 104 109 104 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hlyB </italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hlyD </italic>
###xml 150 161 150 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-raf-hlyA </italic>
###xml 265 270 265 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hlyC </italic>
Restriction map of plasmid pMOhly-Raf The plasmid pMOhly-Raf contains the intact structural genes hlyC, hlyB and hlyD of the hemolysin operon and the c-raf-hlyA fusion hybrid gene. All genes are transcribed from the original cis-acting expression sites in front of hlyC [27]. Abbreviations: ori - origin of replication, bla - ampicillin resistance cassette
###end p 107
###begin p 108
###xml 78 98 78 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella enterica </italic>
###xml 248 250 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
###xml 78 117 <span type="species:ncbi:90371">Salmonella enterica serovar Typhimurium</span>
Identification of the Raf-HlyAs fusion protein by immunoblotting. Cultures of Salmonella enterica serovar Typhimurium SL7207 carrying the plasmids pMOhly1 (lanes 1 and 3) or pMOhly-Raf (lanes 2 and 4) were grown in BHI medium to a density of 5 x 108 cells per ml (optical cell density OD600 = 1). Supernatant proteins precipitated from 1.5 ml of bacterial culture were loaded in lanes 1 and 2; cellular proteins from 0.15 ml of culture were loaded in lanes 3 and 4. The immunoblot was developed with polyclonal anti C-Raf antibodies. The samplers were prepared as described in Materials and Methods.
###end p 108
###begin p 109
###xml 144 146 144 146 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 235 237 235 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 68 72 <span type="species:ncbi:10090">mice</span>
Raf-specific IgG in sera of i.n (A) or p.o/i.v. (B) immunized BxB23 mice (serum dilution 1:200) demonstrated by western blotting. Proteins of 106 lysed SF9 cells expressing recombinant C-Raf [28] (lanes marked with +) or proteins of 106 lysed SF9 cells (- lanes) as control were loaded per lane.
###end p 109
###begin p 110
###xml 46 48 42 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 72 83 68 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella </italic>
###xml 257 259 253 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">6 </sup>
###xml 104 108 <span type="species:ncbi:10090">mice</span>
###xml 136 141 <span type="species:ncbi:10090">mouse</span>
###xml 205 209 <span type="species:ncbi:10090">mice</span>
###xml 609 614 <span type="species:ncbi:10090">mouse</span>
###xml 629 633 <span type="species:ncbi:10090">mice</span>
Increased frequency of IFN-gamma-secreting CD8+ T cells after p.o./i.v. Salmonella infection of C57BL/6 mice (n = 3). For each group, 1 mouse was assessed individually and the remaining splenocytes from 2 mice were pooled in an equivalent proportion. 1 x 106 spleen cells restimulated with either wild-type EL-4 (EL-4) or C-Raf overexpressing EL-4 cell (EL-Raf) and not stimulated (NST) were used. Production of IFN-gamma was determined by flow cytometry after CD8 surface staining and intracellular IFN-gamma staining. Each data point represents the proportion of IFN-gamma positive cells for one individual mouse or two pooled mice respectively. Intracellular staining with an FITC-conjugated isotype control mAb always resulted in <0.05% positive cells.
###end p 110
###begin p 111
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 595 599 <span type="species:ncbi:10090">mice</span>
Effect of immunization on reduction of lung weight. Reduction of lung weight is a mark for a delayed tumor growth. Lung weight of 12-13-month-old BxB23 mice immunized with SL7207/pMO-Raf (i.n., n = 10), SL7207/pMO Raf (p.o./i.v., n = 8), SL7207 (i.n or p.o./i.v., n = 6) and naive (n = 6). Bars represent means and standard deviation of the mice per group. Differences in lung weight (tumor weight) between experimental groups treated with SL7207pMO-Raf (i.n and p.o./i.v.) and all control groups were statistically significant * (P < 0.05), as determined by Student's t test. n - number of the mice
###end p 111
###begin p 112
###xml 37 41 <span type="species:ncbi:10090">mice</span>
Survival of naive BxB11 (■) or BxB11 mice immunized intranasally with SL7207 pMOhly-Raf (▲) in period of one year.
###end p 112
###begin p 113
###xml 31 32 31 32 <sup xmlns:xlink="http://www.w3.org/1999/xlink">R</sup>
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Bacterial strains, plasmids (ApR-ampicillin-resistant), cell lines and mice
###end p 113

